GT Scholar helps develop process to reduce natural resources needed in fuel production

Turning crude oil into fuel and other products requires a distillation process that uses enormous amounts of energy and water. But a Georgia Tech research team that includes GRA Eminent Scholar Rampi Ramprasad may well revolutionize that process: They’ve formulated a new kind of polymer membrane to separate desirable compounds from undesirable ones at the molecular level. The filtration could replace the boiling and cooling process that’s now part of distillation — an approach that accounts for 1% of all of the energy used in the world. With Ramprasad’s expertise and guidance, the team has also created artificial intelligence tools to predict how well different versions of the newly engineered membranes will work, thus speeding development of new membranes for other purposes. Their findings were published in the Oct. 16 edition of  Nature Materials. Above: Ramprasad (left) with Georgia Tech research team members Ryan Lively and M.G. Finn. (Photo by Candler Hobbs.) A good story on a big invention >See the journal article in Nature Materials >

March 24, 2026
Georgia Life Sciences is thrilled to be featured in the very first Atlanta edition of Inside Medicine . This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. Also in the issue, GLS's Kennedy Dumas is featured, sharing her journey on how observation and research evolved into a powerful practice of journaling. As the founder of Stationery Black, she creates notebooks designed to showcase, uplift, and inspire people of color. Read the full article here.
March 24, 2026
B y Trevor Williams , March 24, 2026 | Global Atlanta More than 60 Belgian firms have found a home in Georgia, but nothing on this scale has yet been seen in the state. The amalgam of Belgian investment, carried out over a half-century, translates to about 5,000 current jobs. Gwinnett offered $174 million in incentives to win the project, including property tax abatements, fee waivers and utility improvements, according to Rowen. UCB is set to bring in artificial intelligence, advanced robotics and automation at the site. Biologics are therapies made from living organisms, promising cutting-edge research and manufacturing. Maria Thacker Goethe , president and CEO of Georgia Life Sciences , said the move gives state leaders even more impetus to work collaboratively to build Georgia’s talent pipeline “across every stage — from high school exposure and technical credentials to community college, university, and incumbent-worker upskilling.” “UCB’s decision underscores the strength of Georgia’s talent base, manufacturing capacity, and collaborative business climate, and it reflects the kind of long-term investment that helps build a more resilient U.S. biomanufacturing footprint,” Ms. Goethe told Global Atlanta in an email. Nine of the 16 FDA approvals for UCB drugs and therapies have come within the last three years, showing its prioritization of the U.S. market, where headcount has grown 73 percent since 2017 to 2,000 people. UCB’s products treat severe neurological and immunological conditions like epilepsy, lupus, Parkinson’s disease, rheumatoid arthritis and many more. Read the full article here: UCB Sticks With Georgia, Placing $2 Billion Bet on State’s Life Sciences Ecosystem - Global Atlanta
March 17, 2026
Georgia Life Sciences leads effort to establish bipartisan caucus focused on advancing the state’s growing life sciences economy
MORE POSTS